View Future GrowthCelestra 과거 순이익 실적과거 기준 점검 0/6Celestra 의 수입은 연평균 -43.9%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.2%의 비율로 증가했습니다. 매출은 연평균 8.6%의 비율로 감소해 왔습니다.핵심 정보-43.90%순이익 성장률-11.09%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-8.62%자기자본이익률n/a순이익률-914.51%최근 순이익 업데이트31 Mar 2025최근 과거 실적 업데이트Reported Earnings • Apr 10Full year 2024 earnings released: ₩1,254 loss per share (vs ₩1,576 loss in FY 2023)Full year 2024 results: ₩1,254 loss per share. Revenue: ₩8.50b (down 26% from FY 2023). Net loss: ₩46.9b (loss widened 11% from FY 2023).Reported Earnings • Mar 26Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021)Full year 2022 results: ₩768 loss per share (down from ₩1,214 profit in FY 2021). Revenue: ₩23.1b (down 58% from FY 2021). Net loss: ₩10.2b (down 164% from profit in FY 2021).Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩17.2b (up ₩16.3b from 3Q 2020). Net income: ₩4.63b (up ₩7.77b from 3Q 2020). Profit margin: 27% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.모든 업데이트 보기Recent updatesReported Earnings • Apr 10Full year 2024 earnings released: ₩1,254 loss per share (vs ₩1,576 loss in FY 2023)Full year 2024 results: ₩1,254 loss per share. Revenue: ₩8.50b (down 26% from FY 2023). Net loss: ₩46.9b (loss widened 11% from FY 2023).New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.5b (US$9.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.5b market cap, or US$9.24m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).공시 • Mar 19Clinomics Inc. announced that it has received KRW 5.5 billion in fundingOn March 18, 2025, Clinomics Inc. closed the transaction. The company will now issue KRW 5,500,000,000. The transaction will include participation from new investor Dominate Co., Ltd.공시 • Mar 18Clinomics Inc., Annual General Meeting, Mar 31, 2025Clinomics Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 31, doho-gil, samnam-eup, ulju-gun, ulsan South KoreaNew Risk • Feb 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.4b (US$9.25m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.4b market cap, or US$9.25m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Dec 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩16b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩20.1b market cap, or US$14.4m).New Risk • Nov 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩25.3b market cap, or US$18.1m).New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.8m).공시 • May 30Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million.Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 742,942 Price\Range: KRW 1346 Transaction Features: Subsequent Direct Listing공시 • May 19Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million.Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 742,942 Price\Range: KRW 1346 Transaction Features: Subsequent Direct Listing공시 • May 18Clinomics Inc. announced that it has received KRW 4 billion in fundingOn May 17, 2024, Clinomics Inc. closed the transaction.분석 기사 • Mar 15Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% PlummetUnfortunately for some shareholders, the Clinomics Inc. ( KOSDAQ:352770 ) share price has dived 33% in the last thirty...New Risk • Nov 30New major risk - Revenue and earnings growthRevenue has declined by 77% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 77% over the past year. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩70.2b market cap, or US$54.4m).New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩81.8b market cap, or US$60.7m).New Risk • Sep 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩92.7b market cap, or US$69.5m).New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 77% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (₩90.4b market cap, or US$70.7m).Reported Earnings • Mar 26Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021)Full year 2022 results: ₩768 loss per share (down from ₩1,214 profit in FY 2021). Revenue: ₩23.1b (down 58% from FY 2021). Net loss: ₩10.2b (down 164% from profit in FY 2021).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩9,290, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 21% over the past year.공시 • Dec 02Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in fundingClinomics Inc. announced a private placement of 381,679 convertible registered preferred stock at an issue price of KRW 7,860 for gross proceeds of KRW 2,999,996,940 on December 1, 2022. The transaction will included participation from TS 2018-12 M&A Fund. The preferred stock bear dividend rate 1.0% per year. Each preferred stock is convertible into one common shares. The conversion request period is starting from December 17, 2023 till November 17, 2027. The securties to be issued may be participatory or non-participating, cumulative or non-cumulative. The transaction was approved by the board of directors of the company. The transaction is expected to close on December 16, 2022. The securities to be issued in the transaction will be subject to a 1 year hold period from date of issuance. The company will issue securities through 3rd party allocation increase method.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year.Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩5,640, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 51% over the past year.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩9,180, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩7,960, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past year.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,500, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 58% over the past year.Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩17.2b (up ₩16.3b from 3Q 2020). Net income: ₩4.63b (up ₩7.77b from 3Q 2020). Profit margin: 27% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.공시 • Feb 22Clinomics Inc., Annual General Meeting, Mar 24, 2021Clinomics Inc., Annual General Meeting, Mar 24, 2021, at 11:00 Korea Standard Time.매출 및 비용 세부 내역Celestra가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A352770 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 255,995-54,82724,5771,94631 Dec 248,502-46,92524,4421,94630 Sep 248,246-34,31926,3051,37630 Jun 249,754-33,21524,6141,63631 Mar 249,970-39,75230,2961,88031 Dec 2311,408-42,25730,7161,94130 Sep 2314,597-25,30919,3472,13330 Jun 2314,334-23,01819,7762,33131 Mar 2314,786-15,62614,3592,74031 Dec 2223,083-10,17713,9183,14230 Sep 2246,1276,01313,0723,39930 Jun 2260,88614,10212,4693,28931 Mar 2264,26517,70611,1582,95931 Dec 2155,42615,85310,1842,85230 Sep 2129,106-4099,5433,30030 Jun 2112,785-8,1758,5273,43231 Mar 2112,848-11,1089,3203,74831 Dec 209,820-13,1479,2294,04530 Sep 209,152-11,5257,9363,10230 Jun 209,645-10,0567,4212,59431 Mar 204,327-7,7255,3681,85931 Dec 194,101-5,7603,9711,50231 Dec 182,054-2,2161,872905양질의 수익: A352770 은(는) 현재 수익성이 없습니다.이익 마진 증가: A352770는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A352770은 수익성이 없으며 지난 5년 동안 손실이 연평균 43.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A352770의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A352770은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A352770의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/07/01 02:44종가2025/04/03 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Celestra Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 10Full year 2024 earnings released: ₩1,254 loss per share (vs ₩1,576 loss in FY 2023)Full year 2024 results: ₩1,254 loss per share. Revenue: ₩8.50b (down 26% from FY 2023). Net loss: ₩46.9b (loss widened 11% from FY 2023).
Reported Earnings • Mar 26Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021)Full year 2022 results: ₩768 loss per share (down from ₩1,214 profit in FY 2021). Revenue: ₩23.1b (down 58% from FY 2021). Net loss: ₩10.2b (down 164% from profit in FY 2021).
Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩17.2b (up ₩16.3b from 3Q 2020). Net income: ₩4.63b (up ₩7.77b from 3Q 2020). Profit margin: 27% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 10Full year 2024 earnings released: ₩1,254 loss per share (vs ₩1,576 loss in FY 2023)Full year 2024 results: ₩1,254 loss per share. Revenue: ₩8.50b (down 26% from FY 2023). Net loss: ₩46.9b (loss widened 11% from FY 2023).
New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.5b (US$9.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.5b market cap, or US$9.24m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
공시 • Mar 19Clinomics Inc. announced that it has received KRW 5.5 billion in fundingOn March 18, 2025, Clinomics Inc. closed the transaction. The company will now issue KRW 5,500,000,000. The transaction will include participation from new investor Dominate Co., Ltd.
공시 • Mar 18Clinomics Inc., Annual General Meeting, Mar 31, 2025Clinomics Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 31, doho-gil, samnam-eup, ulju-gun, ulsan South Korea
New Risk • Feb 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.4b (US$9.25m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.4b market cap, or US$9.25m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Dec 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩16b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩20.1b market cap, or US$14.4m).
New Risk • Nov 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩25.3b market cap, or US$18.1m).
New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.8m).
공시 • May 30Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million.Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 742,942 Price\Range: KRW 1346 Transaction Features: Subsequent Direct Listing
공시 • May 19Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million.Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 742,942 Price\Range: KRW 1346 Transaction Features: Subsequent Direct Listing
공시 • May 18Clinomics Inc. announced that it has received KRW 4 billion in fundingOn May 17, 2024, Clinomics Inc. closed the transaction.
분석 기사 • Mar 15Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% PlummetUnfortunately for some shareholders, the Clinomics Inc. ( KOSDAQ:352770 ) share price has dived 33% in the last thirty...
New Risk • Nov 30New major risk - Revenue and earnings growthRevenue has declined by 77% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 77% over the past year. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩70.2b market cap, or US$54.4m).
New Risk • Oct 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩81.8b market cap, or US$60.7m).
New Risk • Sep 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩92.7b market cap, or US$69.5m).
New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 77% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (₩90.4b market cap, or US$70.7m).
Reported Earnings • Mar 26Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021)Full year 2022 results: ₩768 loss per share (down from ₩1,214 profit in FY 2021). Revenue: ₩23.1b (down 58% from FY 2021). Net loss: ₩10.2b (down 164% from profit in FY 2021).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩9,290, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 21% over the past year.
공시 • Dec 02Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in fundingClinomics Inc. announced a private placement of 381,679 convertible registered preferred stock at an issue price of KRW 7,860 for gross proceeds of KRW 2,999,996,940 on December 1, 2022. The transaction will included participation from TS 2018-12 M&A Fund. The preferred stock bear dividend rate 1.0% per year. Each preferred stock is convertible into one common shares. The conversion request period is starting from December 17, 2023 till November 17, 2027. The securties to be issued may be participatory or non-participating, cumulative or non-cumulative. The transaction was approved by the board of directors of the company. The transaction is expected to close on December 16, 2022. The securities to be issued in the transaction will be subject to a 1 year hold period from date of issuance. The company will issue securities through 3rd party allocation increase method.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year.
Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩5,640, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 51% over the past year.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩9,180, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩7,960, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past year.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩6,500, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 58% over the past year.
Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩17.2b (up ₩16.3b from 3Q 2020). Net income: ₩4.63b (up ₩7.77b from 3Q 2020). Profit margin: 27% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
공시 • Feb 22Clinomics Inc., Annual General Meeting, Mar 24, 2021Clinomics Inc., Annual General Meeting, Mar 24, 2021, at 11:00 Korea Standard Time.